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Abstract: Cryptococcal meningitis causes morbidity and mortality worldwide. The burden 
of disease is greatest in middle- and low-income countries with a high incidence of human 
immunodeficiency virus (HIV) infection. Patients taking immunosuppressive drugs and some 
immunocompetent hosts are also at risk. Treatment of cryptococcal meningitis consists of three 
phases: induction, consolidation, and maintenance. Effective induction therapy requires potent 
fungicidal drugs (amphotericin B and flucytosine), which are often unavailable in low-resource, 
high-endemicity settings. As a consequence, mortality is unacceptably high. Wider access to 
effective treatment is urgently required to improve outcomes. For human immunodeficiency 
virus-infected patients, judicious management of asymptomatic cryptococcal antigenemia and 
appropriately timed introduction of antiretroviral therapy are important.
Keywords: cryptococcosis, HIV, immunosuppression, antifungal therapy, immune reconstitu-
tion inflammatory syndrome, antiretroviral therapy
Introduction
Cryptococcosis is an important infectious disease globally. The majority of illness is 
among patients with defective cell-mediated immunity. Human immunodeficiency virus 
(HIV) infection is the main risk factor, accounting for 95% of cases in middle- and 
low-income countries (MLICs)1 and 80% of cases in high-income countries (HICs).2 
Individuals taking immunosuppressive drugs (eg, transplant recipients) constitute 
most of the remaining caseload, although immunocompetent hosts are susceptible in 
some settings.
The most common clinical presentation is cryptococcal meningitis (CM), with 
over 1 million cases and 600,000 deaths per year.3 Nonmeningeal (eg, pulmonary and 
cutaneous) presentations also occur,4 and bloodstream infection (cryptococcemia) may 
disseminate to multiple sites.5
This review describes the epidemiology and management of cryptococcal disease. 
Worldwide distribution of the pathogen is outlined, incidence trends in patients with 
varying risk factors are assessed, and the prognostic implications of differing treat-
ment protocols are highlighted.
Epidemiology of the infectious pathogen
Cryptococci are encapsulated saprophytic yeasts. Two species, transmitted by inhala-
tion, are the principal human pathogens: Cryptococcus neoformans and Cryptococcus 
gattii.6 C. neoformans was identified by Sanfelice in 1894,7,8 and may be divided 
into two subtypes on the basis of capsular agglutination assays.9 C. neoformans var. 
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grubii (capsular serotype D) is the most common, and causes 
82% of cryptococcal disease worldwide. Var. neoformans 
(capsular serotype A) is responsible for 20%–30% of HIV-
associated CM in northern Europe (notably France, Italy, and 
Denmark),9–11 but is less common in other global regions.12,13 
Although both subtypes predominantly cause disease in 
immunocompromised individuals, several reports from the 
US14 and Asia15 suggest that var. grubii cryptococcosis in 
patients with normal immune systems is more common than 
previously assumed. The environmental reservoir of both sub-
types is avian guano, decaying organic matter, and soil.8,16
C. gattii is traditionally associated with illness in 
immunocompetent individuals17–19 from tropical and sub-
tropical regions, including Thailand,20 northern Australia,21,22 
New Zealand, and Papua New Guinea.23–26 More recently, 
four molecular subtypes of C. gattii have been identified with 
distinct epidemiological characteristics that challenge this 
perspective.6 Whilst VGI (var gattii I) is the main subtype in 
 Australasia, an outbreak of disease attributable to VGII has 
been described in immunocompetent patients from British 
Columbia, Canada.27–29 Between 1999 and 2010, 218 cases 
were identified on Vancouver Island.30,31 In 2006, a further 
case was reported on Orcas Island, Washington, USA,32 and 
C. gattii is now endemic throughout the Pacific Northwest of 
the US.29 Sporadic disease has also been notified in other parts 
of North America, including Florida, North Carolina, Rhode 
Island, New Mexico, Michigan, Georgia, and Montana.33 
Additionally, C. gattii subtypes VGIII and -IV are more likely 
to be found in HIV-infected than immunocompetent patients. 
These strains may account for 2.4%–30% of HIV-associated 
cryptococcosis in some parts of Central and South America6 
and southern Africa.34–37 The burden of human disease due to 
C. gattii is probably underrecognized, as many laboratories do 
not undertake detailed speciation of cryptococci.6
The environmental reservoirs of C. gattii are incompletely 
understood. In Australia, India, and other Asian countries, it 
has been isolated in eucalyptus trees.38 In British Columbia, 
it has been isolated from noneucalyptus tree species, soil, 
air, freshwater, and seawater.29 Discovery of this organ-
ism in heterogeneous biogeoclimatic zones suggests that 
its ecological niche was previously underestimated or that 
its distribution is expanding.39,40 Possible explanations for 
a changing distribution include climate change or altered 
land-use practices, such as logging.
HIV as a risk factor
The largest influence on the epidemiology of cryptococ-
cal disease over the last 30 years has been the evolution of 
the HIV pandemic. Figure 1 shows that a fivefold increase 
in the incidence of cryptococcosis in France from 1985 
to 1993 was almost entirely due to burgeoning disease in 
HIV-infected patients, while the number of cases in HIV-
uninfected patients remained stable.41 Similar trends were 
observed in other HICs. In the UK, the number of annual 
cryptococcal case notifications rose from 13 (8% HIV-
associated) in 1982 to 66 (83% HIV-associated) in 1991.42 
Of 517 cryptococcal infections in New York City in 1991, 
96% were HIV-related.43
HIV-infected patients are mainly at risk of cryptococcosis 
when they become very immunosuppressed and their CD4 
count drops below 100 cells/µL.44,45 Consequentially, Figure 1 
indicates that after the development of effective combination 
antiretroviral therapy (ART) in 1997, the upsurge in new 
cases of cryptococcal disease from HICs was reversed and 
incidence began to decline.46–48 From 1997–2001, France 
saw a 46% decrease in cases,41 from 1996 to 2007, incidence 
per 1,000 persons in the UK fell from three to 0.2,49 and 
from 1992 to 2000, incidence per 1,000 persons in Atlanta, 
Georgia, USA fell from 66 to seven.50
Figure 2 shows that disease trends in MLICs have 
been much worse. It is well recognized that sub-Saharan 
Africa has been the global region most heavily affected 
by HIV, with an estimated 2.6 million new infections per 
year at the peak of the epidemic in 1997.51 Contemporane-
ously, in the 1990s, CM became the leading cause of adult 
meningitis in many African countries, including Malawi 
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(27% of cases),52 Zimbabwe (45% of cases),53,54 and South 
Africa (31% of cases).55 Delayed and incomplete access 
to ART meant that unlike Europe and North America, the 
incidence of CM did not recede after the turn of the mil-
lennium; a tertiary referral hospital in Botswana described 
C. neoformans growth from 15% of all cerebrospinal 
fluid (CSF) samples submitted for analysis in 2003,56 and 
a report from Cape Town, South Africa noted that CM 
still accounted for 31% of all inpatient days in new ART 
patients in 2007.57 A similar persistent elevation of the 
cryptococcal disease burden since the 1990s has been 
described from MLICs in Southeast Asia56,58 and Latin 
America.59
In addition to disparities in incidence between HICs 
and MLICs, there are well-documented differences in 
outcomes (Figure 2).3 A combination of earlier access to 
ART and availability of fungicidal drugs has contributed 
to falling mortality in HICs,2,60,61 while the death rate in 
MLICs has been relentlessly high.62 Analysis of pooled 
data from case series, surveillance reports, and clinical 
trials has estimated that the 90-day case-fatality rate from 
HIV-associated CM in East Asia, Oceania, Western Europe 
and the US is 9%, compared with 55% in other parts of 
Asia and South America and 70% in sub-Saharan Africa.3 
Even acknowledging that some North American studies 
exclude the sickest patients,63 and some studies in MLICs 
show better case-fatality rates than others,64–67 these results 
are unacceptable.
Other risk factors
Although HIV is the largest driver of cryptococcal disease, 
it is important to acknowledge other factors. Prior to the 
HIV era in the UK, the incidence of cryptococcosis per 
1,000 persons increased from 1.4 in 1963–1968 to 7.4 
in 1973–1978.68 This was predominantly attributable to 
disease in patients on immunosuppressive medications. 
Use of potent immunosuppressants (eg, corticosteroids, 
calcineurin inhibitors,69 cytotoxic agents,70 and monoclo-
nal antibodies71,72) for transplant conditioning or treatment 
of cancer and inflammatory conditions has continued to 
expand in HICs over the last 30 years, sustaining a small 
but important minority of cryptococcal illness in settings 
where HIV-related cases are in decline.73
Cryptococcosis disease occurs after 2.8%–8% of solid-
organ transplants, and is the third-commonest invasive fungal 
infection in this setting, after Candida and Aspergillus.69,74 
In a retrospective review of US data from 1996 to 2010, 
kidney-transplant recipients were most often affected, fol-
lowed by liver, heart, lung, and pancreas recipients.5 The 
median time to diagnosis after solid-organ transplantation 
is 20 months, and the etiology is normally reactivation of 
latent disease.5,74,75 Symptoms may emerge sooner after lung 
or liver transplants, perhaps because the required level of 
postoperative immunosuppression is higher.69 The overall 
likelihood of cryptococcal disease does not vary between 
patients using tacrolimus, cyclosporine, or azathioprine as 
the primary immunosuppressive agent, but patients who 
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are coadministered high-dose corticosteroids may be at 
higher risk.5
Infrequently, cryptococcal infection is acquired from 
donor tissue. This is particularly suspected if disease occurs 
within 30 days of transplantation, at surgical graft sites, or in 
multiple organ recipients of a single donor.75–77 Screening of 
donors is not routinely performed, but should be undertaken 
if the donor has unexplained pulmonary lesions, undiagnosed 
neurological illness, or unexplained fever with relevant 
comorbid risk factors.76,77
Cryptococcal disease is rare following hematopoietic 
stem cell transplant or corneal tissue transplant.78 Data from 
a consortium of US transplant centers (Transplant-Associated 
Infection Surveillance Network) revealed an incidence of 
only 0.6% in hematopoietic stem cell-transplant recipients 
between 2001 and 2006.79,80 For unknown reasons, the risk 
is higher in autologous than allogenic transplants.78
Non-HIV-infected, nontransplant recipients with cryp-
tococcosis are a heterogeneous group. Except for C. gattii 
outbreaks in immunocompetent hosts, most patients have 
immune dysfunction related to the pathophysiology or treat-
ment of an underlying autoimmune disease, malignancy, or 
innate immunological disorder. It is difficult to generalize 
about these cases, but in HICs they tend to experience higher 
mortality than their HIV-infected counterparts. The reasons for 
this include the effects of underlying illness and late diagnosis, 
because the pathogen was not initially suspected.5,73,81
Clinical presentation
Epidemiological variables, including the nature of immu-
nosuppressive risk factors and pathogen species, influence 
the presentation of cryptococcal disease. CM is the leading 
presentation overall,19,41,42,78 but nonmeningeal manifesta-
tions are proportionally more frequent in non-HIV-infected 
individuals.5,42,73,82 Transplant-associated cryptococcosis is 
often limited to the lungs,83,84 with disseminated or neurologi-
cal disease in 52%–61% of cases.69,84
Presentation of C. gattii infection in immunocompetent 
hosts varies according to molecular subtype. In Australia, 
where the majority of disease is due to VGI, CM is most 
common,6,85 but in North America, VGII disease presents 
with respiratory symptoms in 76%, neurological symptoms 
in 7.8%, and both respiratory and neurological symptoms in 
10.1% of cases.19,24,31
The commonest features of CM are subacute headache 
and confusion. Intracranial pressure (ICP) is often elevated, 
and may cause cranial nerve palsies or seizures. Classical 
features of “meningism” (eg, neck stiffness) occur in less 
than 20% of patients.86 Altered mental state is associated 
with higher mortality.5,50,87
Neurological infection may be complicated by mass 
lesions (cryptococcomas). This is more common with 
C. gattii than C. neoformans. Clinical sequelae of crypto-
coccomas include hydrocephalus and blindness.88,89 Some 
patients require neurosurgical intervention.17,18
Forty percent of patients with CM have ocular involve-
ment, including papilledema and uveitis with multifocal 
chorioretinitis.90,91 Immune-mediated optic nerve dysfunc-
tion and blindness have been particularly reported amongst 
C. gattii patients from Papua New Guinea.54,89,92 The spectrum 
of pulmonary illness ranges from asymptomatic colonization 
to severe, progressive pneumonia and cryptococcomas in the 
lungs. Skin lesions often contain the infecting organism. In 
severely immunocompromised individuals, disseminated 
disease (involvement of two or more sites) may present as 
fever and rash before other symptoms and signs appear.
Investigations
Confirmation of CM requires lumbar puncture (LP) and 
examination of CSF, as shown in Figure 3A. Lack of LP 
equipment may result in underestimation of the disease 
burden in MLICs.93 Typical CSF features include a raised 
opening pressure (reflecting elevated ICP), lymphocytic 
pleocytosis, and evidence of inflammation. However, CSF 
may be normal in 10%–17% of patients,54,94 especially in 
HIV-endemic populations.5 Identification of the infecting 
organism is traditionally done by light microscopy after 
India ink staining, but this method is user-dependent with 
variable sensitivity. Detection of cryptococcal antigen (CrAg) 
Figure 3 (A–C) Diagnosis of cryptococcal meningitis. (A) Lumbar puncture being 
performed on a human immunodeficiency virus-infected patient with suspected 
meningitis in Malawi. (B) Lateral flow immunoassay test strips for cryptococcal 
antigen detection (the strip on the left shows a negative result, indicated by a single 
horizontal “control” band in the center; the strip on the right shows a positive 
result, indicated by adjacent horizontal “control” and “test” bands). (C) Cryptococcus 
neoformans growing on Sabouraud media. images kindly supplied by Kate Gaskell, 
College of Medicine, University of Malawi, and Brigitte Denis, Malawi Liverpool 
wellcome Trust Clinical Research Programme.
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by a latex-agglutination test63 or lateral flow immunoassay 
(LFA) is better (Figure 3B). The lateral flow immunoassay 
is cheaper than latex agglutination,95,96 and may be applied to 
urine samples when CSF is unobtainable.97,98 Fungal culture 
of CSF on Sabouraud media is required to isolate the organ-
ism for antimicrobial susceptibility testing. Characteristic 
colonies grow after 36 hours (Figure 3C).
Radiology has little role in the diagnosis of CM, but com-
puted tomography and magnetic resonance imaging scans 
are necessary to detect complications (eg, cryptococcomas 
and noncommunicating hydrocephalus). These modalities 
are generally unavailable in MLICs.
Nonmeningeal cryptococcosis may be confirmed by  tissue 
sampling for microbiological analysis.  Cryptococcemia is 
identified from fungal blood cultures or CrAg detection in 
serum samples. Asymptomatic antigenemia (a positive serum 
CrAg in the absence of clinical disease) has been described 
in HIV-infected patients, and may predict impending CM. 
Screening and treatment for asymptomatic antigenemia will 
be discussed later.
Treatment and prognosis
The Infectious Diseases Society of America (IDSA)4 and 
World Health Organization (WHO)99 have recently issued 
updated treatment guidelines to reflect advances over the 
last decade, but routine practice in MLICs continues to be 
impeded by poor drug availability. Figure 4 summarizes 
current recommendations.
induction and consolidation antifungal 
therapy for Hiv-associated CM
CM treatment consists of three phases: induction, consolida-
tion, and maintenance. IDSA and WHO guidelines emphasize 
the importance of potent fungicidal drugs during induction 
therapy, because the rate of fungal clearance from the CSF 
during the first 2 weeks, known as early fungicidal activity 
(EFA),100 predicts 10-week survival,101 and CSF sterilization 
by 14 days predicts long-term prognosis.63
Amphotericin B (AmB), the drug with the greatest EFA, 
is administered intravenously for 14 days during induction 
therapy whenever possible. Its activity is concentration-
dependent,102 but the required dose (0.7–1.0 mg/kg) of the 
commonest preparation (AmB deoxycholate [AmBd])33,63–65 
can be nephrotoxic.103,104 A solution in HICs is the use of lipid 
drug formulations with fewer renal side effects, including 
liposomal AmB (LAmB; 3–6 mg/kg/day) and AmB lipid 
complex (ABLC, 5 mg/kg/day).105–107 The cost of these (over 
US$1,000 per day108) is prohibitive for MLICs, so alternative 
strategies, including preemptive hydration and electrolyte 
supplementation, have been developed to minimize the 
toxicity of AmBd.99 Studies in Kampala,62 Cape Town,65 and 
Bangkok109 support this approach.
Even a 2-week course of AmBd (US$12–$15 per day) is 
too expensive for some LICs.110 In this scenario, data from 
South Africa and Malawi have demonstrated that 5–7 days 
of AmBd is better than treatment that is restricted to less 
fungicidal drugs.64,111 AmBd-treated patients who survive 
the first 6 months have a subsequent 5-year survival rate 
of 88%.112 This advocates for investment in early AmBd to 
achieve satisfactory long-term outcomes.
Flucytosine should accompany AmB during induction ther-
apy at an intravenous or oral dose of 100 mg/kg/day.100,113–115 
Omission of this agent has been associated with higher rates 
of mortality,113 treatment failure,116 and late relapse.117 Toxic 
cytopenias can occur during flucytosine therapy, and so regu-
lar full blood counts and therapeutic drug monitoring (TDM) 
are advised by IDSA guidelines.4,57,118 TDM is arduous, and 
the absolute need for it in MLICs was questioned by a recent 
study in Vietnam that did not use TDM but demonstrated 
safe and effective use of AmBd-flucytosine.113
Despite its value, flucytosine remains unlicensed in most 
African and Asian countries,114,119,120 so alternative agents 
have been considered for combination with AmB. The obvi-
ous contender is fluconazole, which is freely distributed in 
MLICs (http://www.pfizer.com/responsibility/global_health/
diflucan_partnership_program), but is fungistatic rather 
than fungicidal in the normal human dose range. Definitive 
evidence to support AmB-fluconazole induction therapy is 
lacking, but reports from several countries describe rapid EFA 
when intravenous AmBd (0.7–1 mg/kg/day) is prescribed 
alongside oral fluconazole (800–1,200 mg/day).109,113,121,122 
A meta-analysis of various induction strategies in resource-
poor settings has described AmBd-fluconazole as cost-
effective.123 The WHO recommends this approach when 
flucytosine cannot be obtained.99
After a 14-day induction phase, treatment proceeds with 
a consolidation phase of 400 mg once daily (od) for a fur-
ther 8 weeks. This dose may be increased to 800 mg when 
gold-standard induction therapy with AmB-flucytosine is 
unavailable.
Gaps in drug provision leave fluconazole as the only agent 
for induction and consolidation therapy in many high-burden 
countries, contributing to significant variation in prognosis. 
The response to this requires discussion. Until recently, 
the routine dose of fluconazole for CM monotherapy was 
200–400 mg od, and 8-week mortality was 78%–90%.86,124 In 
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one South African study from 2006, median patient survival 
on induction- and consolidation-phase fluconazole (400 mg 
od) was only 76 days.125
Such poor outcomes prompted dose escalation. Clini-
cal studies in Uganda and Malawi based on 800 mg od 
induction and 400 mg od consolidation therapy reported 
improved 10-week mortality rates of 58%–60%.87,126 
A further induction-phase dose increase to 1,200 mg 
was  associated with faster EFA126 but did not improve 
survival,126,127 and a pharmacokinetic–pharmacodynamic 
bridging study from a mouse model indicated that 1,200 
mg od will fail to achieve fungal stasis in the CSF of 33% 
of patients.128 An exploratory clinical trial has suggested 
that induction with 1,600–2,000 mg of fluconazole would 
be more efficacious,126,129 but additional evaluation of these 
doses is required. WHO guidelines  currently advocate 
that where fluconazole monotherapy is the only option, 
1,200 mg od should be used for 2-week induction therapy 
followed by a consolidation phase of 800 mg od for 8 
weeks.99
A final option when intravenous drug administration is 
not feasible is a fully oral induction phase of fluconazole and 
flucytosine. Trials in Malawi have confirmed that fluconazole 
(1,200 mg od) and flucytosine (100 mg/kg/day) achieve 
faster EFA and lower 10-week mortality than fluconazole 
alone,70,111,127 suggesting that fluconazole monotherapy should 
be augmented by induction-phase flucytosine wherever 
possible.
Overall, reduced availability of fungicidal drugs contin-
ues to compromise outcomes in high-burden countries. An 
ongoing multicenter clinical trial (Advancing Cryptococcal 
meningitis Treatment in Africa [ACTA]130) in sub-Saharan 
Africa hopes to confirm the shortest, simplest effective 
regimens, but will require backup by universal provision of 
medicines for routine care.
Maintenance antifungal therapy  
for Hiv-associated CM
After consolidation therapy, secondary prophylaxis with 
fluconazole (200 mg od) minimizes the risk of CM relapse.131 
Alternative, less effective maintenance regimens include 
oral itraconazole (200 mg od)117 and intravenous AmBd 
(1 mg/kg/once weekly).132
The required duration of maintenance therapy has 
recently been examined, particularly as the 1-year default 
rate from secondary prophylaxis in some African settings 
exceeds 90%.133,134 In the pre-ART era, lifelong fluconazole 
was recommended after a presentation with CM, but it 
now appears that late relapse is unlikely during success-
ful ART.135–138 International guidelines state that immune 
restoration by ART permits discontinuation of maintenance 
therapy (Figure 4). However, evidence to support cessation of 
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Figure 4 Treatment options for cryptococcal meningitis (CM), summarized from infectious Diseases Society of America and world Health Organization guidelines.
Notes: ain Hiv-infected patients with renal impairment or concern about nephrotoxicity, LAmB or ABLC should be used. bIn settings of limited AmB availability or difficulty 
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induction and consolidation therapy as for Hiv-associated CM. dUndetectable Hiv viral load and CD4 100/µL should be demonstrated on two occasions 6 months apart 
before stopping fluconazole.
Abbreviations: HIV, human immunodeficiency virus; AmB, amphotericin B; LAmB, liposomal amphotericin B (3–6 mg/kg/day); ABLC, amphotericin B lipid complex 
(5 mg/kg/day); od, once daily; PO, per os (by mouth); ART, antiretroviral therapy.
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secondary prophylaxis is weaker when induction/consolida-
tion therapy is not fungicidal (eg, fluconazole monotherapy), 
and isolated CM relapses have been described in patients on 
ART with CD4 counts up to 495 cells/µL.139
Differences in antifungal therapy  
for non-Hiv-associated CM
Treatment of non-HIV-associated CM varies from that 
described above, dependent on characteristics of the host 
and pathogen (Figure 4). Patients developing CM after 
solid-organ transplant often take nephrotoxic immunosup-
pressants (tacrolimus, cyclosporine or sirolimus) to prevent 
graft rejection, and 25% of transplant recipients have renal 
dysfunction at CM diagnosis. Therefore, kidney-friendly 
liposomal preparations of AmB (eg, LAmB or ABLC) are 
recommended during induction therapy.4 It is uncertain 
whether immunosuppressive therapy should be stopped 
during CM treatment; this may accelerate eradication of the 
pathogen, but poses a risk of proinflammatory immune recon-
stitution syndrome or transplant rejection.140 Although clear 
evidence is lacking, some authors report good outcomes with 
a staged reduction in immunosuppressive therapy alongside 
antifungal drugs.141
Secondary fluconazole prophylaxis in transplant recipi-
ents may stop after 6–12 months, as the late cryptococcal 
relapse rate is only 1%–3%.142 There is no standard regimen 
for non-HIV, nontransplant patients with CM. Some authors 
advocate a longer (4–6 weeks) induction phase of AmB/
flucytosine (Figure 4), while others favor a standard 2-week 
induction phase. Consolidation and maintenance therapy are 
identical to transplant recipients. C. gattii infection should 
be treated with the same drugs as C. neoformans, but the 
response to therapy may be slower, due to higher azole 
minimum inhibitory concentrations143,144 and poor drug 
penetration of cryptococcomas.17,18,85
Asymptomatic antigenemia  
and primary prophylaxis
Between 4% and 20% of patients with newly identi-
fied HIV infection and a CD4 count ,150 cells/µL have 
a positive serum CrAg test in the absence of clinical 
cryptococcosis.145–147 Asymptomatic antigenemia predicts 
impending CM,148 and is associated with increased mortali-
ty.149 Serum CrAg screening of new HIV patients is being 
implemented in South Africa,150 prompting debate on the use 
of preemptive therapy for those at highest risk.
Treatment of asymptomatic antigenemia is not recom-
mended in HICs,4 but some studies support fluconazole 
therapy for serum CrAg-positive patients in MLICs.151–153 
A management algorithm is shown in Figure 5.154 However, 
deployment of preventive screening and therapy strategies 
is operationally difficult, and an implementation study in 
Kenya achieved effective fluconazole administration for 
only 52% of eligible patients.155 The benefit of presumptive 
therapy for asymptomatic antigenemia will depend on the 
logistics of integrating this strategy into routine practice at 
ART clinics.
An alternative means of CM prevention is primary 
prophylaxis with fluconazole for all patients with CD4 
counts ,100 cells/µL, irrespective of serum CrAg test-
ing. Studies of this approach in Thailand156 and Uganda157 
demonstrated that fluconazole 200 mg once daily reduced 
the incidence of CM, but there was no reduction in overall 
mortality and rates of fluconazole-resistant Candida albicans 
infection increased.158 The cost-effectiveness of no preven-
tive treatment, therapy for asymptomatic antigenemia, or 
primary prophylaxis is likely to vary between regions, based 
on the underlying epidemiology of cryptococcal infection 
and availability of ART.
Additional therapeutic considerations
Outcomes from CM may be improved by reduction of raised 
ICP during early therapy, careful management of immune 
reconstitution inflammatory syndrome (IRIS) and appropri-
ately timed ART initiation for HIV-infected patients.
Reducing raised intracranial pressure
Increased ICP (25 cm/H
2
O) is associated with greater 
CSF fungal burden159 and higher mortality.160 Regular CSF 
drainage by serial LPs is recommended.115,161–164 Insertion of 
a temporary CSF-drainage catheter165 or ventriculoperitoneal 
shunt may also be used.166 Drug therapy (eg, acetazolamide or 
corticosteroids) to reduce CSF pressure or prevent  blindness 
in CM patients is not beneficial, and acetazolamide may 
cause harm.88,160,167
Managing immune reconstitution inflammatory 
syndromes
IRIS in CM patients occurs when host immune recovery 
triggers inflammatory reactions to persistent fungal anti-
gens. There are two main forms: unmasking and paradoxical 
(Figure 6).168
Unmasking IRIS occurs in HIV-infected patients when 
subclinical cryptococcal disease emerges after ART is 
 commenced. This might be prevented by careful pre-ART 
screening. However, late ART is generally associated with 
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Paradoxical IRIS in the central nervous system has a 
mortality of up to 36%.174,175 Risk factors include severe 
disease at presentation and slow fungal elimination.176,177 The 
benefit of anti-inflammatory drugs (eg, corticosteroids100) is 
unproven.178 Highly fungicidal induction-phase therapy and 
rapid CSF steri lization is the best way to minimize unwanted 
reactions.179,180
Combining anticryptococcal and anti-Hiv 
medications
In HIV-associated CM, IRIS is more likely during immune 
reconstitution from lower baseline CD4 counts, and is 
Diagnosed with CM Initial recovery
CM deterioration/
new features of
cryptococcal disease
Effective anti-fungal therapy
Immune recovery due to
• ART initiationa (HIV patients)
• Reduction of immunosuppressive drugs (eg, transplant recipients)
• Clinical improvement (all patients, including immunocompetent)
Paradoxical IRIS
Unmasking IRIS
Diagnosed with HIV
no features of CM
Initiated on ARTa
Immune restoration
rising CD4 count
First presentation
of CM
Figure 6 Types of immune restoration inflammatory syndrome (IRIS) in cryptococcal disease.
Note: aHiv-associated CM iRiS should occur within 12 months of ART initiation.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; CM, cryptococcal meningitis.
lower survival,169 and patients who are already on HIV therapy 
when they present with CM tend to have better outcomes,64,170 
so excessive delays should be avoided.
Paradoxical IRIS is best described in HIV-associated 
CM patients who initially respond to antifungal drugs and 
then deteriorate within 12 months of starting ART. Studies 
from South Africa and Ethiopia estimate an incidence of 
7%–33%.171–173 Paradoxical IRIS also affects solid organ-
transplant patients when antirejection medications are inter-
rupted during CM therapy,141 and apparently healthy hosts 
may suffer from reactivation of immune defenses that were 
previously overwhelmed by high fungal burden.
Patient tests HIV positive
Blood taken for CD4 count
CD4 >100 cells/µL No fluconazole prophylaxis
ART initiated in accordance with national protocol
Symptom screen/LP to exclude CM
CD4 ≤100 cells/µL
Point of care serum CrAg screening test
CrAg negative
CrAg positive
CM diagnosed Treat as CM
Induction and consolidation phase as per national
protocol (fungicidal drugs where available)
CM not diagnosed
Treat as asymptomatic antigenemia
Fluconazole 800 mg od for 2 weeks
then 400 mg od for 8 weeks
Maintenance phase therapy
Continue fluconazole 200 mg od
Initiate ART at 2–10 weeks
Discontinue fluconazole after effective immune restorationa
Figure 5 A screening and management strategy for asymptomatic antigenemia.
Notes: aUndetectable Hiv viral load and CD4 100/µL should be demonstrated on two occasions 6 months apart before stopping fluconazole. Jarvis JN, Govender N, 
Chiller T, et al, J Int Assoc Physicians AIDS Care (Chic) (11), pp 374–379, copyright © 2012 by SAGE Publications. Adapted by permission of SAGE Publications.154
Abbreviations: HIV, human immunodeficiency virus; CrAg, cryptococcal antigen; LP, lumbar puncture; CM, cryptococcal meningitis; od, once daily; ART, antiretroviral 
therapy.
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Table 1 Prospective open-label randomized trials to assess optimal timing of antiretroviral therapy (ART) initiation in human 
immunodeficiency virus (HIV)-infected patients with cryptococcal meningitis (CM)
Study and site Study design Baseline CD4  
count, cells/μL,  
median (IQR)
CM induction- 
phase drugs
Initiation of  
ART during  
CM therapy
Study outcomes
Zolopa et al,182  
USAa and  
South Africa
282 patients with  
Ois (35 with CM) 
48-week follow-up
29 (10–55) Not stated ,2 weeks versus  
4–32 weeks
All patients: fewer AiDS events/
deaths in early (20 of 141 [14%]) 
versus late (34 of 141 [24%]) ART 
(OR 0.5, 95% Ci 0.3–0.9)
CM patients: no difference in  
AiDS events/deaths in early  
(one of 13 [8%]) versus late (three 
of 22 [14%]) ART (OR 0.5, 96%  
Ci 0.1–5.7)
Makadzange et al,184  
Zimbabwe
54 patients with CM 
3-year follow-up
37 (17–69) Fluconazole only ,72 hours versus  
10 weeks
Higher mortality in early (23 of 28 
[82%]) versus late (12 of 26 [46%]) 
ART (HR 2.3, 95% Ci 1.1–4.9)
Bisson et al,183  
Botswana
27 patients with CM 
24-week follow-up
29 (11–50) AmB + fluconazole ,7 days versus  
28 days
No difference in mortality in early 
(two of 13 [15%]) versus late (five 
of 14 [36%]) ART (OR 0.3, 95% 
Ci 0.1–2.1)
Boulware et al,185  
Uganda and  
South Africa
177 patients with CM 
6-month follow-up
19 (9–69) AmB + flucytosine ,14 days versus  
28 days
Higher mortality in early 
(40/88 [45%]) versus late (27 of 
89 [30%]) ART (HR 1.7, 95% Ci 
1.1–2.8; P=0.03)
Note: aincludes patients from Puerto Rico.
Abbreviations: IQR, interquartile range; AIDS, acquired immunodeficiency syndrome; OR, odds ratio; HR, hazard ratio; CI, confidence interval AmB, amphotericin B; 
Ois, opportunistic infections.
influenced by the timing of ART introduction. Balancing the 
danger of early mortality from advanced immunosuppres-
sion against that of accelerated immune recovery is difficult, 
and best practice remains to be established. A retrospective 
study of mortality after ART initiation in Thailand at time 
points 1–12 months into CM therapy did not show any 
association between timing of ART and outcome.181 Table 1 
summarizes subsequent prospective trials.135,136,182–185 The 
most convincing data come from a recent study in Uganda 
and South Africa, which was terminated early because ART 
initiation within the first 28 days of CM treatment led to 
a higher risk of IRIS and death.185 Introduction of ART 
4–10 weeks after starting antifungal treatment is currently 
considered the safest approach.
Conclusion
Advanced HIV infection continues to drive cryptococcal 
disease worldwide. Patients on immunosuppressive drugs 
and some immunocompetent hosts are also at risk. Although 
treatment with potent drug combinations provides effective 
cure, poor availability of fungicidal drugs in MLICs results 
in high case-fatality rates. Expanded provision of fungicidal 
treatment is urgently required. Ongoing research on man-
agement of asymptomatic antigenemia and optimal timing 
of ART initiation is important to improve the prognosis of 
HIV-associated CM.
Disclosure
The authors report no conflicts of interest in this work.
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